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Open and endovascular repair of type B aortic
dissection in the Nationwide Inpatient Sample
Teviah Sachs, MD, Frank Pomposelli, MD, Robert Hagberg, MD, Allen Hamdan, MD,
Mark Wyers, MD, Kristina Giles, MD, and Marc Schermerhorn, MD, Boston, Mass
Background: The use of stent grafts and mortality of stent graft repair of type B thoracic aortic dissection (TBAD) is not
well defined. We sought to determine national estimates for the use and mortality of thoracic endovascular aortic repair
(TEVAR) for TBAD in the United States.
Methods: Records of the Nationwide Inpatient Sample (NIS) database between 2005 and 2007 were examined.
International Classification of Diseases, 9th edition (ICD-9) diagnosis codes were used to select patients who underwent
open or TEVAR with a stent graft for a diagnosis of thoracic aortic dissection or thoracoabdominal aortic dissection. We
excluded patients with a diagnosis code for aortic aneurysm and those with procedure codes for cardioplegia or for
operations on heart vessels or valves, which were considered type A dissections (TAAD). The remaining patients were
considered as TBAD. We compared demographics and comorbidities, as well as adjusted complications and mortality
rates, between patients undergoing TEVAR vs open repair.
Results:We identified an estimated 10,466 repairs for dissection of the thoracic or thoracoabdominal aorta (open, 8659;
TEVAR, 1818). Of these, 464 had a diagnosis of aortic aneurysm, and 5002 patients were considered TAAD. Of
nonaneurysmal dissections, 5000 repairs were considered TBAD (open, 3619; TEVAR, 1381). The endovascular patients
were older and had greater comorbidities, although only cardiac disease, renal failure, hypertension, and peripheral
vascular disease were statistically significant. In-hospital mortality was 19% for open repair vs 10.6% for TEVAR (odds
ratio [OR], 2.24; 95% confidence interval [CI], 1.36-3.67; P < .01). In-hospital mortality was significantly higher with
open repairs coded as emergent admissions (20.1% vs 13.1%; P .03), but did not reach statistical significance for elective
admissions (12.3% vs 4.8%; P .09). Cardiac complications (12.4% vs 4.9%, P< .01), respiratory complications (7.7% vs
4.3%, P  .02), genitourinary complications (9.0% vs 2.5%, P < .01), hemorrhage (14.0% vs 2.8%, P < .01), and acute
renal failure (32.1% vs 17.2%, P < .01) were more frequent in the open repair group. Median length of stay was greater
in the open repair group (10.7 vs 8.3 days, P < .01).
Conclusion: For patients with a diagnosis of TBADwho undergo repair, the endovascular approach is being used for older
patients with greater comorbidities, yet has reduced morbidity and in-hospital mortality. The use of endovascular stent
graft repair for type B thoracic aortic dissection merits further longitudinal analysis. ( J Vasc Surg 2010;52:860-6.)The overall incidence of aortic dissection has been esti-
mated to be anywhere from 2.9 to as high as 3.5 cases/
100,000 per year.1-4 Approximately 20% of these patients die
before hospitalization, and another 30% die in the hospital.5
Estimates of 5-year survival after initial hospitalization range
from 30% to 80%.2,3,6 Whereas Stanford type A acute aortic
dissections (TAAD) are treated almost exclusively as a surgical
emergency, Stanford type B acute aortic dissections (TBAD)
are typically treated medically, with estimates approaching
75% to 90% of TBAD being treated without surgery.
7,8 Sur-
gery is usually reserved for patients with rupture, branch vessel
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860compromise, rapid expansion, or for persistent symptoms of
uncontrolled hypertension or pain. For those who do un-
dergo open repair, recent studies suggest that there is minimal
difference in mortality between TAAD and TBAD.
9-11
Still, relatively few studies have looked at the role of
thoracic endovascular aortic repair (TEVAR) for TBAD,
and those that have are small, single-institution stud-
ies.12,13 Larger studies are mostly meta-analyses and, even
so, have relatively low numbers.14,15 Mortality estimates of
TEVAR are between 1.2% and 14%, depending on acuity of
dissection.16-18 Yet, in addition to mortality, there is signif-
icant morbidity, including retrograde type A dissection (3%
to 11%), stroke (1.4% to 20%), paraplegia (0% to 13.3%),
endoleak (7% to 47%), and visceral or peripheral infarc-
tion.9,12-20
Owing to the relative paucity of national data, the true
utilization, morbidity, and mortality of TEVAR in patients
with TBAD are still not clear. We used the Nationwide Inpa-
tient Sample (NIS) database to better examine outcomes of
mortality and major morbidity in patients with TBAD.
METHODS
This is a retrospective cohort study. We used the Inter-
national Classification of Diseases, 9th edition (ICD-9) di-
agnosis codes to identify all patients in the Nationwide
g excl
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section (441.01) or thoracoabdominal aortic dissection
(441.03). Endovascular repair of the thoracic aorta was not
available through ICD-9 diagnosis code until 2005, limit-
ing our study to the 3-year period from 2005 through
2007. To study acute dissection and not aneurysmal disease
or chronic dissections that present with aneurysm, we sep-
arated all patients with diagnosis codes for aneurysm (441.1
to 441.9). To isolate TBAD from TAAD, we further sepa-
rated patients with procedure codes for cardioplegia
(39.63), valve repair (35.00-35.99), or operations on ves-
sels of the heart (36.00-36.99, 37.0, 37.2, 37.31-37.90,
37.93-37.99), which would be more likely with TAAD.We
then separated the remaining patients into two cohorts for
comparison: those who received endovascular stent graft
repair (39.73) vs those receiving open repair (38.45, 39.57;
Fig 1).
Demographics identified were age, gender, race, and
hospital teaching status. Admission status, as identified by
ICD-9 code, was available for 4181 patients (83.6%).
These were grouped for statistical analysis as either emer-
gent (combining codes for emergent and urgent admis-
sions) or elective. Comorbid conditions were prior myocar-
Fig 1. Algorithm describindial infarction, peripheral vascular disease, congestive heartfailure, cardiac disease, neurologic disorders, diabetes, hy-
pertension, chronic pulmonary disease, renal disease, and
obesity.21
We identified the use of TEVAR for all thoracic aortic
dissections over time, looking primarily at the outcome of
in-hospital mortality. Additional outcomes measured were
complications, length of stay (LOS), discharge status, and
total hospital charges. Complications included hemorrhage,
stroke, peripheral vascular complications, cardiac complica-
tions, respiratory complications, genitourinary complications,
acute renal failure, and gastrointestinal complications. Com-
parisonsweremade using univariate analysis, limitedmultivar-
iate logistic regression (controlling for age and gender only),
and extended multivariate logistic regression (controlling
for all previously identified comorbidities as well as hospital
teaching status). Predictors of death were also examined.
Variables are presented as total counts, percentages, medi-
ans, and means with standard deviation. Statistical signifi-
cance is presented by P values or odds ratios (OR) with 95%
confidence intervals (CI). We used SAS 9.2 software and
SAS Callable SUDAAN 10 software (SAS Institute, Cary,
NC) for all statistical analyses. The t test was used for
usions and analysis cohorts.continuous variables and 2 analysis for categoric variables.
cic en
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During the 3-year period, 10,466 patients identified
with a diagnosis of thoracic or thoracoabdominal aortic
dissection underwent operative repair (Table I, A). We
excluded 464 patients who had a diagnosis of aortic aneu-
rysm and 5002 patients considered as having TAAD. Of
dissections without a code for aneurysm, 5000 repairs
(49.9%) were considered TBAD, with 3619 open (72.4%)
and 1381 TEVAR (27.6%). Of these, 31 patients (0.62%)
had codes for both TEVAR and open repair and were
included in the TEVAR group for all outcome analyses
because we could not differentiate whether these were
hybrid procedures or conversions from TEVAR to open
repair. There were 1035 patients (20.7%) whose diagnosis
was for thoracoabdominal aortic dissection (open, 71%;
TEVAR, 29%) and 3965 patients (79.3%) with a code for
thoracic aortic dissection (open, 73%; TEVAR, 27%).
The number of NIS hospitals sampled that performed
open repair increased from 134 to 155 (11.9%) between
2005 and 2006. Those performing TEVAR, however, in-
creased from 19 to 54 (184%) during the same period, as
did hospitals performing both open and TEVAR proce-
dures, increasing from 14 to 49 (250%). Between 2006 and
2007, though, these numbers remained relatively stable
(open, 155 to 150; TEVAR, 54 to 55; both, 49 to 44). This
represents an unweighted 20% sample of hospitals nation-
wide. Since September 2005, TEVAR use for TBAD
ranged from 25% to 55% per month (Fig 2).
Demographics and comorbidities. Patients under-
going TEVAR vs open repair were similar with respect to
age (median age, 62.7 vs 60.0 years; P .0738) and gender
(female, 33.6% vs 34.7%, P  .99). TEVAR patients were
more likely to have cardiac disease (7.0% vs 2.5%, P .01),
peripheral vascular disorders (31.7% vs 16.2%, P  .01),
renal failure (16.4% vs 12.6%, P .047), and hypertension
(73.3% vs 65.5%, P  .01). Patients undergoing open
repair had higher rates of valvular disease (22.2% vs 10.3%,
P  .01). The overall trends remained between TEVAR
and open cohorts when they were separated by emergent/
urgent and elective admission (Table I, B).
Mortality. Mortality for TBAD was significantly higher
for open repair (19.5% vs 10.3%, P  .01; Table II, A).
Patients coded as thoracoabdominal dissections also showed
Table I. A, Open and endovascular repair by type of aorti
Year No.
All type B
Open
No. (%)
TEVAR
No. (%)
Total 5000 3619 (72.4) 1381 (27.6)
2005 1336 1248 (93.4) 88 (6.6)
Sept-Dec 485 404 (84.6) 81 (15.4)
2006 1910 1191 (62.4) 719 (37.6)
2007 1754 1180 (67.3) 574 (32.7)
TEVAR, Thoracic endovascular aneurysm repair.
aInternational Classification of Diseases, 9th edition diagnosis code for thorahigher mortality with open repair (16.9% vs 9.5%, P .03),as did those coded as thoracic dissections (26.4% vs 13.3%,
P  .048). These trends remained when compared by
emergent (20.1% vs 13.1%, P  .03) or elective (12.3% vs
4.8%, P  .09) admission. When adjusted for age and
gender, in-hospital mortality was more than twice as likely
with open repair (OR, 2.24; 95% CI, 1.36-3.67; P  .01).
This persisted when further adjusted for comorbidities, and
the ORs did not appreciably change.
The mortality rate for patients undergoing open repair
was 26.6% for those coded as thoracoabdominal dissection
vs 16.9% for those coded as thoracic dissection (OR, 1.83;
95% CI, 1.21-2.76; P .01; Table II, B). This difference in
mortality did not extend to TEVAR (thoracoabdominal,
13.1% vs thoracic, 9.5%; P  .47).
Morbidity. Open repair had higher rates of cardiac
complications (12.4% vs 4.9%, P  .01), respiratory com-
plications (7.7% vs 4.3%, P  .02), genitourinary compli-
cations (9.0% vs 2.5%, P  .01), hemorrhage (14.0% vs
2.8%, P .01), and acute renal failure (32.1% vs 17.2%, P
.01; Table II, B). A significant difference was noted when
those coded as thoracoabdominal repair were compared
with those coded as thoracic repair: cardiac complications
were 17.4% vs 10.8% (OR, 1.88; 95% CI, 1.15-3.05; P 
.01) and acute renal failure was 38.2% vs 29.4% (OR, 1.51;
section: 2005 through 2007a
Thoracic Thoracoabdominal
Open
No. (%)
TEVAR
No. (%)
Open
No. (%)
TEVAR
No. (%)
84 (72.7) 1081 (27.3) 735 (71.0) 300 (29.0)
56 (92.4) 79 (7.7) 290 (96.9) 11 (3.1)
08 (81.5) 70 (18.5) 96 (95.7) 11 (40.3)
28 (63.7) 529 (36.3) 263 (58.2) 190 (41.8)
00 (67.9) 472 (32.1) 180 (64.0) 102 (36.1)
dovascular aneurysm repair was not available until September 2005.
Percentage of Repairs Using TEVAR by Month
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Fig 2. Percentage of repairs that were performed using stent graft
(TEVAR) for type B aortic dissection: 2005 through 2007. a5.6%
of total sample missing. bFood and Drug Administration approval
for TEVAR for descending thoracic abdominal aortic aneurysm
was granted in March of 2005. cInternational Classification of
Disease, 9th edition diagnosis code for TEVAR was not available
until September 2005.c dis
28
9
3
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1095% CI, 1.07-2.14, P  .02).
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ing mortality were open repair (OR, 1.98; 95% CI, 1.28-
3.05; P .01), median age 65 years (OR, 1.56; 95% CI,
1.14-2.16; P .01), emergency admission (OR, 1.59; 95%
CI, 1.18-2.13; P  .01), dissection coded as thoracoab-
dominal (OR, 1.74; 95% CI, 1.25-2.33; P  .01), and
congestive heart failure (OR, 1.63; 95% CI, 1.18-2.25; P
.01). Hypertension was also protective (OR, 0.59; 95% CI,
0.44-0.79; P  .01). Valvular disease, despite being more
prominent in the open repair cohort, was not a predictor of
mortality (Table III).
Charges and LOS. TEVAR had significantly shorter
in-hospital LOS (median, 8.3 vs 10.7 days, P  .01) and
lower charges associated with the total hospital LOS (me-
Table I. B, Demographics and comorbidities for open rep
all patients as well as by admission typea
Comorbidities
All type B
Open, %
(n  3619)
TEVAR, %
(n  1381) P
Age 65 years 39.2 45.5 .0
Teaching hospital 75.0 79.2 .2
Female 34.7 33.6 .9
Race .1
White 48.8 47.7
Black 12.6 11.2
Congestive heart failure 10.1 10.0 .9
Cardiac disease 2.5 7.0 .0
Valvular disease 22.2 10.3 .0
Peripheral vascular disease 16.2 31.7 .0
Neurologic disorders/paralysis 5.5 3.2 .1
Chronic obstructive pulmonary
disease 17.7 21.3 .1
Diabetes 6.5 10.6 .0
Renal failure 12.6 16.4 .0
Obesity 6.8 6.2 .8
History of recent myocardial
infarction 1.2 4.6 .0
Hypertension 65.5 73.3 .0
aAdmission data available for 83.6% of sample (84.5% of TEVAR, 83.3% of
bValues of P  .05 are considered significant.
Table II. A, Mortality of thoracic endovascular
aneurysm repair (TEVAR) and open repair: Overall and
by admission typea,b
Mortality
Open
%
TEVAR
% OR (95% CI) P
All type B dissections 19 10 2.24 (1.36-3.67) .01
Emergent/urgent
admission
20 13 1.72 (1.04-2.86) .04
Elective admission 12 5 3.21 (0.80-12.96) .09
CI, Confidence interval; OR, odds ratio.
aAdjusted for age, gender, comorbidities, and admission type.
bAdmission data available for 83.6% of sample (84.5% of TEVAR, 83.3% of
open repairs).dian, $121,041 vs $158,841; P  .01).DISCUSSION
In 1994, Dake et al22 showed the utility of TEVAR for
patients with descending thoracic aortic aneurysm who
were otherwise poor candidates for open surgery and dem-
onstrated its use 5 years later in acute thoracic aortic dissec-
tion.23 The U.S. Food and Drug Administration approved
TEVAR for repair of descending thoracic aneurysm in
March 2005.24 Although there has been an increase since
that time in the number of patients with TBAD who are
undergoing off-label treatment with TEVAR,25,26 its util-
ity in acute and stable TBAD is unclear.
10,17 To better
nd thoracic endovascular aneurysm repair (TEVAR) for
Type B aortic dissections only
Emergent/urgent admit Elective admit
Open, %
n  2520)
TEVAR, %
(n  764) Pb
Open, %
(n  494)
TEVAR, %
(n  403) Pb
38.1 40.6 .62 35.8 51.3 .03
73.5 78.0 .60 76.7 78.5 .84
35.4 36.9 .75 28.6 27.7 .89
.41 .78
68.1 69.8 70.8 77.6
20.3 17.1 19.3 15.2
9.7 8.3 .55 7.4 12.6 .30
20.9 13.1 .04 25.1 6.0 .01
14.6 31.4 .01 14.9 30.7 .01
4.8 1.9 .08 6.2 5.0 .70
16.7 19.9 .40 21.2 22.5 .83
5.7 7.0 .58 7.3 17.2 .07
11.9 15.1 .33 11.5 16.2 .38
6.3 2.6 .01 6.4 16.4 .04
1 3.8 .03 3.0 8.8 .13
2.4 5.0 .07 3.0 11.2 .08
63.9 66.7 .49 57.4 83.0 .01
repairs).
Table II. B, Morbidity of thoracic endovascular
aneurysm repair (TEVAR) and open repair for all type B
aortic dissectionsa
Complication
Open
%
TEVAR
% OR (95% CI) P
Cardiac 12 5 3.07 (1.41-6.69) .01
Respiratory 8 4 2.33 (1.01-5.37) .05
Genitourinary 9 3 5.72 (2.13-15.37) .01
Hemorrhage 14 3 7.74 (3.56-16.85) .01
Acute renal failure 32 17 2.59 (1.66-4.03) .01
Stroke 6 3 2.23 (0.93-5.39) .07
Peripheral vascular 1 2 0.71 (0.19-2.58) .60
Acute myocardial
infarction 3 1 1.66 (0.46-5.99) .44
CI, Confidence interval; OR, odds ratio.
aAdjusted for age, gender, comorbidities, and admission type.air a
b (
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examined the weighted estimates of the NIS from 2005 to
2007, adds to the collective understanding of this modality
in the treatment of TBAD.
Our study found that approximately 27% of repairs for
TBAD were performed using an endovascular approach.
Patients with a diagnosis of TBAD who underwent open
repair had a nearly twofold higher odds of in-hospital
mortality. This difference was maintained when compared
by emergent vs elective admission. For open repair, but not
for TEVAR, patients with a diagnosis code for thoracoab-
dominal dissection had higher mortality than did those
with a code for thoracic dissection.
Although age and gender were similar across both
groups, the TEVAR patients were sicker, with higher pro-
portions of cardiac disease, peripheral vascular disease, renal
failure, and hypertension. Outcomes of respiratory compli-
cations, cardiac complications, acute renal failure, and gas-
trointestinal complications tended to occur more often in
the open group. The only comorbidity that was signifi-
cantly higher in the open group was valvular disease; how-
ever, this was not a predictor of mortality in our analysis.
Using the combined data from the European Collabo-
rators on Stent-Graft Techniques for Aortic Aneurysm
Repair (EUROSTAR) and the United Kingdom Thoracic
Endograft Registry Collaborators, Leurs et al14 showed
overall 30-day mortality for patients who underwent stent
graft repair of thoracic aortic dissections—acuity of dissec-
tion undefined—(106 TBAD, 7 TAAD, 18 unknown type)
to be 8.4%. Recently, Xu et al,12 in a study of 84 patients
with chronic (1 month) TBAD undergoing endovascular
repair, showed a 30-day mortality of 1.2%. In the acute
setting of TBAD, Neuhauser et al
13 documented a mortal-
ity with TEVAR of 14% (n  28).
The International Registry of Acute Aortic Dissection
(IRAD) has provided further insight into acute aortic dis-
sections in the population.11With their initial data, patients
with diagnosed acute TBAD who underwent repair dem-
onstrated an in-hospital mortality for open surgery of
32.1% (n  56) vs 9.6% for medical therapy alone (n 
282) and 6.5% for endovascular repair (n  46).27 How-
ever, this included a relatively small number of operative
Table III. Predictors of mortality for all type B aortic
dissections
Predictors of mortality OR (95% CI) P
Open repair 1.98 (1.28-3.05)
Emergent admission 1.59 (1.18-2.13) .01
Thoracoabdominal dissection 1.74 (1.25-2.33) .01
Congestive heart failure 1.63 (1.18-2.25) .01
Hypertension 0.60 (0.45-0.80) .01
Age 65 years 1.56 (1.14-2.16) .01
Female gender 1.05 (0.80-1.36) .74
Valvular disease 0.95 (0.70-1.28) .73
Renal failure 0.81 (0.51-1.29) .37
CI, Confidence interval; OR, odds ratio.repairs (n  102) performed at high-volume referral cen-ters and may not reflect the national experience. This is
highlighted by our data, where mortality for the TEVAR
patients classified as emergent admissions was not as low as
seen in the IRAD data. In IRAD, they have further shown
that operative TAAD (n  320; mortality, 26.6%) has a
similar mortality to operative TBAD (n  41; mortality,
32.1%).11
We found in-hospital mortality of TBAD for operative
emergency admissions was 20.1% with open repair and
13.1% with TEVAR. For nonemergent repairs, in-hospital
mortality decreased for both groups (12.3% and 4.8%,
respectively). Although we could not account for addi-
tional procedures such as fenestration or renal stenting, we
did see higher mortality for open repair in thoracoabdomi-
nal dissections—which would be more likely to involve
such procedures—compared with thoracic dissection
(26.7% vs 16.9%, P  .01).
This is not a randomized controlled trial and, therefore,
is subject to confounding. By using multivariate logistic
regression analysis, we have attempted to adjust for known
confounders. The NIS database uses administrative dis-
charge data, which provides a large volume of patients but
brings with it inherent limitations. Accuracy of coding for
comorbid conditions is variable28,29 and often selected by
the data entry personnel, and so those diagnoses with
higher reimbursement rates are favored.30
It is unlikely that we excluded all TAAD in our analysis.
Our study showed a ratio of operative TBAD to operative
TAAD of just 1:1. This is higher than other stud-
ies,8,10,11,27 which reflects the difficulty of using the NIS
database for such a study. Just as diagnosis codes are limited
to 15 entries, so too are procedure codes. Still, as previous
reports have shown, the mortality rates for open repair in
the acute setting are similar for TAAD (26.6%) and TBAD
(32.1%).11,27 With this slightly lower mortality, the further
exclusion of any remaining TAAD in our analysis would
likely strengthen our findings for acute dissection. Further-
more, ICD-9 coding for endovascular repair of the thoracic
aorta (39.73) is unlikely to be misidentified. Therefore, the
decrease in mortality we have shown with TEVAR vs open
repair, both overall and in emergent admissions, is note-
worthy.
The inability to specifically quantify or distinguish the
complexity of presenting symptoms or anatomic variations
of the individual patients can lead to considerable selection
bias. Rödel et al31 showed that even highly trained endo-
vascular surgeons demonstrate substantial variability in
their estimation of individual patient suitability for
EVAR.31 Patient selection due to indications, such as vis-
ceral or renal involvement or acute expansion, cannot be
accounted for, nor is the length of the dissection and degree
of patency of the false lumen—which has been correlated to
outcome—available.32 Although the absence of indications
for surgery from this data set could have biased our results,
the 10% mortality we found for TEVAR (n  1381) was
similar to the 9.6% that was seen for IRAD patients—with
indications for surgery—who were treated with medical
therapy alone (n  282).33
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mortality for TEVAR in TBAD. However, we have no data
available on midterm or long-term durability of TEVAR in
these patients. Mid-term follow-up studies for TEVAR in
abdominal aortic aneurysm have shown that the greatest
risk of death comes in the immediate perioperative period,
which lends reliability to our findings.33,34However, in our
study of EVAR and open repair of abdominal aortic aneu-
rysms in the Medicare population, long-term survival for
EVAR and open repair eventually became similar.35 Long-
term data are necessary to see if this also holds true for
endovascular repair in TBAD.
CONCLUSIONS
Despite these limitations, we believe this study is valu-
able because it demonstrates that approximately 25% of
repairs for TBAD are TEVAR. The endovascular approach
is being used for older patients, with greater comorbidities,
and shows reduced morbidity and mortality, and does so at
less cost and shorter hospital stay. Although there are
limitations to our data, those patients identified as emer-
gent admissions are likely to have acute dissections, and
TEVAR mortality in this TEVAR subgroup—although
higher than what was reported in the IRAD study—is still
lower than what was seen with open repair. For selected
patients and institutions, TEVAR is being used in the
setting of TBAD with reasonably low mortality. The dura-
bility of TEVAR for patients in whom it is anatomically
suitable and whose indication warrants repair remains an
area of interest, worthy of further study.
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Dr Christopher J. Kwolek (Newton, Mass). I would like to
congratulate Drs Sachs and Schermerhorn on bringing us another
interesting paper utilizing large administrative databases, such as
the National Inpatient Sample, to gain a better understanding of
what is occurring nationally in the open and endovascular manage-
ment of type B thoracic aortic dissection. I would also like to thank
the authors for providing me with a copy of their manuscript in a
timely fashion.
Dr Sachs and colleagues have shown that use of thoracic endo-
vascular aortic repair (TEVAR) leads to a decreased in-hospital mor-
tality of 13% compared with an openmortality of 20% for emergent
repair of type B dissection, and a decreased mortality of 4.8% vs
12.8% for elective open repair. This occurred despite the fact that
the TEVAR procedures were being performed on older patients
with greater comorbidities.
The authors have accurately pointed out the limitations of
using administrative databases, including the inability to drill down
on specific details about individual patients, including indications
for surgery, such as visceral malperfusion or aneurysmal dilatation,
and the details about the operative or endovascular repair. In
addition, they have pointed out the coding inaccuracies in these
databases with respect to determining comorbidities, outcomes,
and even the specific types of procedures being performed. Never-
theless, these results agree with the data presented by the European
Collaborators on Stent-Graft Techniques for Aortic Aneurysm
Repair (EUROSTAR) collaborators and several small single-center
series. Our practice at the Massachusetts General Hospital also
utilizes TEVAR as the first-line therapy for the management of
acute complicated type B aortic dissection in conjunction with
endovascular fenestration and stenting of the visceral and iliac
vessels as necessary.
I have several comments/questions for the authors:
1. Since the majority of patients with uncomplicated Type B
dissection are initially treated with medical management, is it
possible to compare the outcomes of these patients using the
same databases?
2. Management of chronic type B dissections is often performed
months or years after the initial dissection and often for aneu-
rysmal degeneration. Yet, your analysis excluded patients with a
diagnosis of both dissection and thoracic aneurysm, thus you
may be missing some of these chronic patients. Furthermore, inexcluded any patients undergoing open repair with cardioplegia
or cardiac assist. Yet, this will miss the patients undergoing open
repair for chronic dissection using atriofemoral bypass to min-
imize the risk of paraplegia and visceral ischemia.
3. You state that any admissions that had both an open and a
TEVAR code were considered a failure of TEVAR that was
converted to open. While the numbers are small, this may also
represent combined procedures where an open and an endo-
vascular hybrid procedure are being performed together and
may begin to occur more frequently in the future.
4. Since the majority of patients with uncomplicated type B dis-
section are initially treated with medical management, is it
possible to compare the outcomes of these patients using the
same databases?
Dr Teviah Sachs. Thank you, Dr Kwolek, those are all very
valid points you bring up. For your first question: Although it is
possible to look at these patients, it was not the focus of our study.
However, if one were to look at those patients, we expect it would
be difficult to exclude type A dissections in this database, as our
methodology excludes type A dissections based on surgical proce-
dure codes. Therefore, we would expect the mortality to be
over-estimated as most type A dissections who are not operated
upon, die.
As to your second question: Our purpose was to analyze the
national outcomes for acute type B dissections and to that end we
did exclude those patients you mentioned, which were more likely
chronic dissections. As for those patients using atriofemoral by-
pass, we don’t expect to have missed those patients. There are
separate codes for cardiopulmonary bypass, which are distinct from
cardioplegia and circulatory arrest, as would be used in atriofemo-
ral bypass procedures.
Your third question, regarding hybrid or staged procedures:
You rightly point out that these could have been combined proce-
dures. However, there were relatively few patients (50), and
rather than exclude these patients, we chose to include them as
“intention to treat.” Since they could have been included in either
group, and would likely bias that group’s mortality, we chose to
bias against TEVAR. As a matter of fact, when isolated, their
outcomes were actually worse than either cohort: open or endo-
vascular.
